PMC:7195088 / 16245-16438 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"745","span":{"begin":152,"end":171},"obj":"Chemical"},{"id":"910","span":{"begin":7,"end":15},"obj":"Disease"}],"attributes":[{"id":"A745","pred":"tao:has_database_id","subj":"745","obj":"MESH:C558899"},{"id":"A910","pred":"tao:has_database_id","subj":"910","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"s with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonav"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T79","span":{"begin":7,"end":15},"obj":"Disease"}],"attributes":[{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"s with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonav"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T68","span":{"begin":22,"end":27},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T69","span":{"begin":85,"end":90},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"s with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonav"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T107","span":{"begin":22,"end":27},"obj":"Chemical"},{"id":"T108","span":{"begin":152,"end":171},"obj":"Chemical"},{"id":"T109","span":{"begin":152,"end":161},"obj":"Chemical"},{"id":"T110","span":{"begin":162,"end":171},"obj":"Chemical"},{"id":"T112","span":{"begin":176,"end":185},"obj":"Chemical"}],"attributes":[{"id":"A107","pred":"chebi_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A108","pred":"chebi_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A109","pred":"chebi_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A110","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A112","pred":"chebi_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"}],"text":"s with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonav"}

{"project":"LitCovid-sentences","denotations":[{"id":"T103","span":{"begin":17,"end":58},"obj":"Sentence"},{"id":"T104","span":{"begin":59,"end":135},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"s with COVID-19. Open-label RCT (NCT04252885, recruiting). Primary endpoint: rate of virus inhibition at day 0, 2, 4, 7, 10, 14 and 21.\n• Comparison of lopinavir/ritonavir vs. lopinavir/ritonav"}